Although members of the class I
phosphoinositide 3-kinases (PI3Ks) have been implicated in neutrophil inflammatory responses, the contribution of the individual PI3K
isoforms in neutrophil activation has not been tractable with the non-selective inhibitors,
LY294002 and
wortmannin. We have developed a novel series of PI3K inhibitors that is selective for PI3K delta, an
isoform expressed predominantly in hematopoietic cells. In addition to being selective between members of class I PI3Ks, representatives of these inhibitors such as IC980033 and
IC87114 did not inhibit any
protein kinases tested. Utilizing these inhibitors we report here a novel role for PI3K delta in neutrophil activation. Inhibition of PI3K delta with IC980033 and
IC87114 blocked both fMLP- and TNF1 alpha-induced neutrophil
superoxide generation and
elastase exocytosis. The PI3K delta inhibitor
IC87114 also blocked TNF1 alpha-stimulated
elastase exocytosis from neutrophils in a mouse model of
inflammation. To our knowledge, this is the first in vivo efficacy demonstration of a PI3K delta inhibitor in an animal model. Inhibition of PI3K delta, however, had no effect on in vitro neutrophil bactericidal activity and Fc gamma R-stimulated
superoxide generation. Thus, PI3K delta plays an essential role in certain signaling pathways of neutrophil activation and appears to be an attractive target for the development of an anti-inflammatory therapeutic.